Pharmaceutical Giant Faces Mounting Challenges as Analyst Turns Bearish
Published on 10/01/2025 at 20:09 | Redaktion boerse-global.de
Danish pharmaceutical leader Novo Nordisk is confronting significant headwinds as market sentiment shifts dramatically. Morgan Stanley has issued a stark reassessment of the company’s prospects, downgrading its rating and slashing the price target substantially.
In a move that caught market attention, Morgan Stanley analyst Thibault Boutherin reduced Novo Nordisk’s rating from “Equal Weight” to “Underweight” – effectively recommending investors sell their positions. The firm simultaneously cut its price target from $59 to $47, representing a substantial 20% reduction.
The downgrade reflects growing concerns about prescription trends for Novo Nordisk’s flagship medications Ozempic and Wegovy in the United States, where growth has stalled after a period of remarkable expansion.
Competitive Pressures Intensify Across Markets
Morgan Stanley’s... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
